a Department of Health Science and Technology, Faculty of Medicine , Aalborg University , Aalborg , Denmark.
b Center for Clinical and Basic Research (CCBR) , Aalborg , Denmark.
Curr Med Res Opin. 2019 Apr;35(4):715-723. doi: 10.1080/03007995.2018.1519503. Epub 2018 Sep 28.
Vitamin D levels have been linked to certain pain states, including migraine. This study investigated whether vitamin D supplementation would be beneficial for adult patients with migraine (ClinicalTrials.gov Identifier: NCT01695460).
A randomized, double-blinded, placebo-controlled parallel trial was conducted in migraine patients (36 women and 12 men, 18-65 years of age). A 4-week baseline period was conducted before randomization to 24 weeks of treatment. Participants were assigned to receive D3-Vitamin (n = 24, 18 women and 6 men, 100 μg/day D3-Vitamin) or placebo (n = 24, 18 women and 6 men). Migraine attacks and related symptoms were assessed by self-reported diaries. The response rate (i.e. experiencing a 50% or greater reduction in migraine frequency from baseline to week 24), change in migraine severity, and number of migraine days were recorded. Changes in migraine-related symptoms, HIT-6 scores, and pain sensitivity tests (pressure pain threshold and temporal summation) were also evaluated. Serum levels of both 25 (OH)D and 1,25 (OH)D were assessed from baseline to week 24.
The number of headache days changed from 6.14 ± 3.60 in the treatment group and 5.72 ± 4.52 in the placebo group at baseline to 3.28 ± 3.24 and 4.93 ± 3.24 by the end of the trial, respectively. Migraine patients on D3-Vitamin demonstrated a significant decrease (p < .001) in migraine frequency from baseline to week 24 compared with placebo. However, migraine severity, pressure pain thresholds, or temporal summation did not show a significant change. 25(OH)D levels increased significantly for the D3-Vitamin group during the first 12 weeks of treatment. There was no significant change in 1,25(OH)D. No side-effects were reported or noted.
D3-Vitamin was superior to placebo in reducing migraine days in migraine patients. Larger studies are required to confirm that vitamin D might be one of the prophylactic options for adult patients with migraine.
维生素 D 水平与某些疼痛状态有关，包括偏头痛。本研究调查了维生素 D 补充剂是否对偏头痛成年患者有益（ClinicalTrials.gov 标识符：NCT01695460）。
对偏头痛患者（36 名女性和 12 名男性，年龄 18-65 岁）进行了一项随机、双盲、安慰剂对照的平行试验。在随机分组前进行了为期 4 周的基线期，然后进行了 24 周的治疗期。参与者被分配接受 D3-维生素（n=24，18 名女性和 6 名男性，每天 100μg D3-维生素）或安慰剂（n=24，18 名女性和 6 名男性）。偏头痛发作和相关症状通过自我报告的日记进行评估。记录了反应率（即从基线到第 24 周偏头痛发作频率减少 50%或更多）、偏头痛严重程度的变化以及偏头痛天数。还评估了偏头痛相关症状、HIT-6 评分和疼痛敏感测试（压痛阈值和时间总和）的变化。从基线到第 24 周评估了血清中 25（OH）D 和 1,25（OH）D 的水平。
治疗组的头痛天数从基线时的 6.14±3.60 降至试验结束时的 3.28±3.24，安慰剂组从 5.72±4.52 降至 4.93±3.24。与安慰剂相比，服用 D3-维生素的偏头痛患者从基线到第 24 周偏头痛发作频率显著降低（p<0.001）。然而，偏头痛严重程度、压痛阈值或时间总和没有明显变化。D3-维生素组在治疗的前 12 周内 25（OH）D 水平显著升高。1,25（OH）D 没有显著变化。未报告或注意到任何副作用。
D3-维生素在减少偏头痛患者的偏头痛天数方面优于安慰剂。需要更大的研究来证实维生素 D 可能是偏头痛成年患者的一种预防选择之一。
Zotero 插件